Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Special-effect drug for treating asthma

A technology for asthma and drugs, which is applied in the field of medicine, can solve the problems of ineffective treatment, temporary cure, and low cure rate, and achieve good non-specific immune effect and good curative effect

Inactive Publication Date: 2014-03-26
解玉启
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Hormone injection therapy can only relieve the clinical symptoms of some patients. The administration method of this therapy is not easy to master, and the curative effect is not ideal. Therapy has been used for a long time (it has been used for more than one hundred years), but it still cannot completely cure asthma. Because the treatment period of this therapy is too long (the treatment period generally takes 3-5 years), it is difficult for patients to persist. The cure rate of the therapy is low, and most patients lose confidence because of the ineffective treatment, give up halfway, and give up the treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

example 1

example 2

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a special-effect drug for treating asthma, which is composed of a drug I, a drug II and a drug III; the drug I comprises the following components by weight: 0.016g of dead bacillus calmette guerin vaccine, 1.071g of potato starch, 0.3g of aminophylline, 0.001g of ketotifen, 0.005g of dioxopromethazine, 0.025g of levomisole, 0.03g of bromhexine and 0.8g of green tea; the drug II comprises the following components by weight: 1.4g of fructus schisandrae, 1.4g of astragalus and 0.3g of cinnamon; and the drug IIT comprises the following components by weight: 1.2g of radix codonopsis, 1.2g of astragalus, 0.3g of epimedium and 0.4g of gypsum. The special-effect drug disclosed by the invention is prepared on the basis of combination of Chinese and western medicine sciences, has remarkable treatment effect, and treats both symptoms and root causes.

Description

technical field [0001] The invention relates to a specific drug for treating asthma, belonging to the technical field of medicine. Background technique [0002] Asthma, also known as allergic bronchial asthma, is a worldwide frequently-occurring disease, listed by the World Health Organization as one of the four major chronic diseases, and has a very high mortality rate (the death rate occupies the fourth place among all diseases, and Taiwan's famous singer Teresa Teng died of an asthma attack). In recent years, the proportion of children among asthmatic patients has shown an upward trend (the incidence rate is 50%), which has aroused great concern from insiders. [0003] Studies have shown that asthma is generally a chronic airway inflammation caused by the participation of eosinophils, mast cells, T cells and other cells and cell components. This inflammation leads to airway hyperresponsiveness and narrowing of the airways, which manifests as recurrent attacks, wheezing,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/82A61K36/57A61K36/481A61P11/06A61K31/137A61K31/429A61K31/4535A61K31/522A61K31/5415A61K33/06A61K35/74
Inventor 解玉启
Owner 解玉启
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products